Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2010
11/18/2010US20100291133 Recombinant protein containing a c-terminal fragment of plasmodium msp-1
11/18/2010US20100291132 Streptococcus uberis adhesion molecule
11/18/2010US20100291131 Clostridial toxin netb
11/18/2010US20100291130 Cloned genome of infectious hepatitis c virus strain hc-tn and uses thereof
11/18/2010US20100291129 Norovirus and sapovirus antigens
11/18/2010US20100291128 Novel compositions and vaccines against influenza a and influenza b infections
11/18/2010US20100291127 Tumor associated antigen peptides and use of same as anti-tumor vaccines
11/18/2010US20100291126 Protein showing enhanced expression in cancer cells
11/18/2010US20100291125 Eta-1 gene and methods for use
11/18/2010US20100291124 Extracellular serine protease
11/18/2010US20100291123 T Cell Receptor CDR3 Sequences and Methods for Detection
11/18/2010US20100291122 Method for enhancing immune response with peptide
11/18/2010US20100291121 Tumour-Specific Animal Proteins
11/18/2010US20100291120 Peptides regulating the surface expression of the t cell receptor
11/18/2010US20100291119 Alpha B crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
11/18/2010US20100291118 Class of Gamma Delta T Cells Activators and Use Thereof
11/18/2010US20100291117 Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
11/18/2010US20100291116 Microparticle comprising cross-linked polymer
11/18/2010US20100291115 Pharmaceutical composition for the sublingual administration of vaccines, method for the preparation of the same and uses thereof
11/18/2010US20100291114 Crystal structures and methods using same
11/18/2010US20100291113 Treatment of Proliferative Disorders Using Antibodies to PSMA
11/18/2010US20100291112 Recombinant, Single-Chain, Trivalent Tri-Specific or Bi-Specific Antibody Derivatives
11/18/2010US20100291111 Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell Proliferation
11/18/2010US20100291110 Compositions and Methods for Regulating NK Cell Activity
11/18/2010US20100291109 Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
11/18/2010US20100291108 Antibodies to irem-1
11/18/2010US20100291107 High affinity human antibodies to human il-4 receptor
11/18/2010US20100291106 Compositions and methods for antibodies targeting complement protein c3b
11/18/2010US20100291105 Agent for the treatment of malignant diseases
11/18/2010US20100291104 Bordetella outer-membrane protein antigens and methods of making and using the same
11/18/2010US20100291103 Polypeptides, antibody variable domains and antagonists
11/18/2010US20100291102 Therapeutic Agent
11/18/2010US20100291101 New anti-irc85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof
11/18/2010US20100291100 Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions
11/18/2010US20100291099 Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
11/18/2010US20100291098 Diabetic nephropathy therapies
11/18/2010US20100291097 Monoclonal antibody
11/18/2010US20100291096 Therapeutic peptides for the treatment of metatstatic cancer
11/18/2010US20100291095 Identification of a conserved region of plasmodium falciparum msp3 targeted by biologically active antibodies
11/18/2010US20100291094 Nucleic acid encoding 238p1b2 useful in detecting cancer
11/18/2010US20100291093 Antibody-mediated disruption of quorum sensing in bacteria
11/18/2010US20100291092 Compositions and methods for detection, prevention, and treatment of anthrax and other infectious diseases
11/18/2010US20100291091 Cancer associated gene ly6k
11/18/2010US20100291090 Prion Protein as a Receptor for Amyloid-Beta Oligomers
11/18/2010US20100291089 Ligand of regulating immune response, and use thereof in treating an immune response-related disease
11/18/2010US20100291088 Il-18 binding proteins
11/18/2010US20100291087 Method of treating fibrproliferative disorders
11/18/2010US20100291086 Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
11/18/2010US20100291085 Antibodies to ox-2/cd200 and uses thereof in inhibiting immune responses
11/18/2010US20100291084 Use of il-23 antagonists for treatment of infection
11/18/2010US20100291083 Novel Analgesic Treatment with Prolonged Effect
11/18/2010US20100291082 Antigen presenting cell targeted anti-viral vaccines
11/18/2010US20100291081 Rage fusion proteins
11/18/2010US20100291080 Compositions and methods for tissue repair
11/18/2010US20100291079 Heterodimeric Follicle Stimulating Hormone-Fc (FSH-Fc) Fusion Proteins for the Treatment of Infertility
11/18/2010US20100291078 Proteinaceous binding molecules comprising purification tags or inert variable domains
11/18/2010US20100291077 Methods and Compositions for Modulating ERBB2 Activity
11/18/2010US20100291076 Antibodies specific for dkk-1 and their uses
11/18/2010US20100291075 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing Antibodies
11/18/2010US20100291074 Cyclophilin d-amyloid beta interaction potentiates mitochondrial dysfunction in a transgenic mouse model of alzheimer's disease
11/18/2010US20100291073 Methods of reducing eosinophil levels
11/18/2010US20100291072 Antibody variants with faster antigen association rates
11/18/2010US20100291071 Antibody Specific Binding to A-Beta Oligomer and the Use
11/18/2010US20100291070 Type iii secretion system component protein pa1698 of pseudomonas aeruginosa
11/18/2010US20100291069 Methods of treating a diabetic embryopathy
11/18/2010US20100291068 Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
11/18/2010US20100291067 Methods And Compositions Relating to Viral Latency
11/18/2010US20100291066 Donor specific antibody libraries
11/18/2010US20100291065 Compositions for Protein Delivery and Methods of Use Thereof
11/18/2010US20100291037 Immunogenicity using a combination of dna and vaccinia virus vector vaccines
11/18/2010US20100291032 Compositions and methods for the identification of inhibitors of retroviral infection
11/18/2010US20100291028 Use of il-18 inhibitors for treatment and/or prevention of peripheral vascular diseases
11/18/2010US20100291027 Hyaluronic acid (ha) injection vehicle
11/18/2010US20100291026 Piperidine inhibitors of janus kinase 3
11/18/2010US20100291025 Indazole inhibitors of tyrosine kinase
11/18/2010US20100291024 Methods and compositions for the treatment of proliferative and pathogenic diseases
11/18/2010US20100291023 Method for extending the half-life of exogenous or endogenous soluble molecules
11/18/2010US20100291001 Metalloproteinase-binding proteins
11/18/2010US20100290996 Methods and compositions based on culturing microorganisms in low sedimental fluid shear conditions
11/18/2010US20100290994 O-Methylated Rapamycin Derivatives For Alleviation And Inhibition Of Lymphoproliferative Disorders
11/18/2010US20100290993 Antibodies to IL-6 and use thereof
11/18/2010US20100290992 Nanoparticle nucleic acid binding compound conjugates forming i-motifs
11/18/2010US20100290984 Anti-mrp3 antibodies and methods of use
11/18/2010US20100290982 Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
11/18/2010CA2799081A1 Vaccine immunotherapy
11/18/2010CA2763359A1 New human rotavirus strains and vaccines
11/18/2010CA2762033A1 Meningococcal vaccine based on lipooligosaccharide (los) and neisseria meningitidis protein
11/18/2010CA2761924A1 Menigococcus vaccine containing lipooligosaccharide (los) from modified strains of l6 immunotype neisseria meningitidis
11/18/2010CA2761917A1 Method for detoxification of lipopolysaccharide (lps) or of lipid a of gram-negative bacteria
11/18/2010CA2761916A1 Method for admixing the lipopolysaccharide (lps) of gram-negative bacteria
11/18/2010CA2761891A1 Anti-axl antibody
11/18/2010CA2761885A1 Methods and compositions for treating lupus
11/18/2010CA2761800A1 Anti-human cd52 immunoglobulins
11/18/2010CA2761736A1 Enhanced immune response in avian species
11/18/2010CA2761665A1 Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
11/18/2010CA2761648A1 Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
11/18/2010CA2761457A1 Immortalized avian cell lines and use thereof
11/18/2010CA2760465A1 Method for orthopoxvirus production and purification
11/18/2010CA2759836A1 Humanized axl antibodies
11/17/2010EP2251426A1 Mammalian-type glycosylation in plants
1 ... 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 ... 1823